他汀类药物与新发糖尿病的风险、机制及研究进展

Statins and the Risk, Mechanism and Research Progress of New Onset Diabetes Mellitus

他汀类药物是3-羟基-3-甲基戊二酰辅酶A (3-hydroxy-3methylglutaryl-coenzyme A, HMG-CoA)还原酶抑制剂,通过降低低密度脂蛋白胆固醇,发挥对心脑血管的保护作用,目前主要用于心血管疾病的一级和二级预防。但是随着他汀类药物的广泛应用,其长期服用的安全性也日益引起人们的重视,近年来,研究发现他汀治疗有增加新发糖尿病的风险。本文主要综述了他汀类药物致新发糖尿病的可能机制及研究进展,旨在为临床用药提供参考。

Statins are a kind of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which play a protective role on cardiocerebrovascular by reducing low-density lipoprotein cholesterol (LDL-C) and have been widely utilized in the primary and secondary prevention of coronary athero-sclerotic heart disease (ASCVD). However, with the widespread use of statins, the safety of long-term treatment with statins is also receiving increasing attention. Recent clinical studies have demon-strated that statin treatment increases the risk of new-onset type 2 diabetes. This article mainly re-views the possible mechanism and research progress on the risk of new-onset diabetes induced by statins, aiming to provide reference for clinical medication.